Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
Clinical Trials
380
293 active
Approvals
18
Total approvals
Agencies
4
Regulatory bodies
Founded
N/A
Active, not recruiting
288
75.8%
Completed
28
7.4%
Not yet recruiting
5
1.3%
Recruiting
54
14.2%
Suspended
3
0.8%
Terminated
1
0.3%
Unknown
1
0.3%
- New comprehensive market reviews reveal robust clinical trial activity for both gouty arthritis (gout) and bronchiectasis, with major pharmaceutical companies leading development efforts across multiple regions. - The reports highlight significant participation from industry leaders including AstraZeneca, Novartis, and Takeda in gout research, while bronchiectasis trials feature prominent involvement from Boehringer Ingelheim, Insmed, and Gilead Sciences. - Both therapeutic areas demonstrate global research distribution across G7 and E7 countries, with detailed analysis of trial phases, enrollment trends, and sponsor participation patterns. - Recent developments include Vast Therapeutics completing its first milestone in a Phase 1 clinical program for bronchiectasis treatment in November 2025.
- The global biotechnology market is projected to surge from $1.55 trillion in 2024 to $5.71 trillion by 2034, representing a robust 13.9% compound annual growth rate. - Tissue engineering and regeneration technologies captured the largest market share at 19.17% in 2024, while chromatography is emerging as the fastest-growing segment with a 15.1% CAGR. - North America dominates the market with 37.42% share in 2024, while Asia Pacific is positioned as the fastest-growing region with a 14.8% CAGR driven by demographic strength and healthcare expansion. - Bio-pharmacy applications lead the market with 42% share in 2024, fueled by increasing demand for biologics and personalized treatments over traditional chemical-based drugs.
- The CHAPAS-4 trial found that tenofovir alafenamide (TAF) plus emtricitabine (FTC) suppressed HIV in 6% more children than standard backbone treatments while being more cost-effective. - Dolutegravir (DTG) emerged as the superior anchor drug, achieving full viral suppression in 10% more children than lopinavir/ritonavir and atazanavir/ritonavir, while also being the least costly option. - Children receiving newer drug combinations showed improved growth, bone health, and cholesterol levels, reinforcing WHO recommendations for DTG-based regimens as preferred second-line treatments.
- A recent study suggests that the FDA's Risk Evaluation and Mitigation Strategy (REMS) for CAR T-cell therapy may be overly restrictive, impacting patient accessibility. - The study found that the incidence of cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) is low after the first two weeks post-CAR T infusion. - Researchers propose a more flexible approach to monitoring, with a mandatory 2-week period near the treatment center, followed by individualized assessments. - Revisiting REMS mandates could reduce the physical and financial burden on patients, potentially improving access to CAR T-cell therapy, especially for underserved populations.
